NCT05485987View on ClinicalTrials.gov

A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia

PHASE2CompletedINTERVENTIONAL

Enrollment

5

Participants

Timeline

Start Date

October 12, 2022

Primary Completion Date

August 29, 2024

Study Completion Date

August 29, 2024

Conditions

Friedreich Ataxia

Interventions

DRUG

Vatiquinone

Vatiquinone will be administered per dose and schedule specified in the arm.

Trial Locations (1)

19104

The Children's Hospital of Philadelphia, Philadelphia

Sponsors

Lead Sponsor

PTC Therapeutics

All Listed Sponsors

lead

PTC Therapeutics

INDUSTRY

NCT05485987 - A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia | Biotech Hunter | Biotech Hunter